CPHA Canvax

"In 25 U.S. jurisdictions, decreases in case incidence rate ratios for unvaccinated versus fully vaccinated persons with and without booster vaccine doses were observed when the Omicron variant emerged in December 2021. Protection against infection and death during the Delta-predominant period and against infection during Omicron emergence were higher among booster vaccine dose recipients, especially among persons aged 50–64 and ≥65 years.

COVID-19 vaccination protected against SARS-CoV-2 infection, even as the Omicron variant became predominant. All eligible persons should stay up to date with COVID-19 vaccination." - COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021

Additional Authors: Shivani Arora, Tigran Avoundjian, Abiola O. Awofeso, Jason Barnes, Nagla S. Bayoumi, Katherine Busen, Carolyn Chang, Mike Cima, Molly Crockett, Alicia Cronquist, Sherri Davidson, Elizabeth Davis, Janelle Delgadillo, Vajeera Dorabawila, Cherie Drenzek, Leah Eisenstein, Hannah E. Fast, Ashley Gent, Julie Hand, Dina Hoefer, Corinne Holtzman, Amanda Jara, Amanda Jones, Ishrat Kamal-Ahmed, Sarah Kangas, FNU Kanishka, Ramandeep Kaur, Saadiah Khan, Justice King, Samantha Kirkendall, Anna Klioueva, Anna Kocharian, Frances Y. Kwon, Jacqueline Logan, B. Casey Lyons, Shelby Lyons, Andrea May, Donald McCormick, Erica Mendoza, Lauren Milroy, Allison O’Donnell, Melissa Pike, Sargis Pogosjans, Amy Saupe, Jessica Sell, Elizabeth Smith, Daniel M. Sosin, Emma Stanislawski, Molly K. Steele, Meagan Stephenson, Allen Stout, Kyle Strand, Buddhi P. Tilakaratne, Kathryn Turner, Hailey Vest, Sydni Warner, Caleb Wiedeman, Allison Zaldivar, Benjamin J. Silk, Heather M. Scobie

Rating See Comments Ratings

Category:

Vaccine Safety and Development,Research and Development,Vaccine Effectiveness and Efficacy,Monitoring and Surveillance,Outbreaks and Pandemics,COVID-19,Vaccine Preventable Disease Surveillance,National Surveillance Vaccine Safety and Development
Research and Development
Vaccine Effectiveness and Efficacy
Monitoring and Surveillance
Outbreaks and Pandemics
COVID-19
Vaccine Preventable Disease Surveillance
National Surveillance

0 Comments

Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.

All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.